Organogenesis Holdings Inc (NASDAQ:ORGO) Director Avista Capital Managing Member bought 860,900 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average price of $5.99 per share, with a total value of $5,156,791.00.
Avista Capital Managing Member also recently made the following trade(s):
- On Tuesday, September 10th, Avista Capital Managing Member bought 537,000 shares of Organogenesis stock. The shares were purchased at an average price of $5.18 per share, with a total value of $2,781,660.00.
Shares of ORGO opened at $5.73 on Thursday. Organogenesis Holdings Inc has a 1-year low of $3.56 and a 1-year high of $310.90. The company has a debt-to-equity ratio of 3.78, a current ratio of 1.51 and a quick ratio of 1.14. The company has a fifty day moving average of $4.69.
Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $64.95 million during the quarter, compared to analysts’ expectations of $61.00 million. As a group, sell-side analysts predict that Organogenesis Holdings Inc will post -0.5 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new stake in Organogenesis in the second quarter valued at $200,000. Bank of New York Mellon Corp purchased a new stake in Organogenesis in the second quarter valued at $210,000. Northern Trust Corp lifted its position in Organogenesis by 134.3% in the second quarter. Northern Trust Corp now owns 41,066 shares of the company’s stock valued at $312,000 after acquiring an additional 23,540 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Organogenesis by 36.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 86,495 shares of the company’s stock valued at $658,000 after acquiring an additional 23,180 shares during the last quarter. Finally, Moors & Cabot Inc. purchased a new stake in Organogenesis in the second quarter valued at $694,000. 1.68% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on ORGO shares. Zacks Investment Research downgraded shares of Organogenesis from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. Credit Suisse Group started coverage on shares of Organogenesis in a research note on Monday, August 26th. They set an “outperform” rating for the company. Finally, BTIG Research set a $12.00 target price on shares of Organogenesis and gave the stock a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $10.80.
Organogenesis Company Profile
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
Recommended Story: What is dividend yield?
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.